New challenges may lie ahead for the pharmaceutical industry -
What’s next for drug pricing in the US?
Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers,...more
On October 7, 2019, California became the first state to enact legislation—Assembly Bill 824 ("AB 824")—rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive. This alert...more
10/18/2019
/ Anti-Competitive ,
Antitrust Violations ,
Burden-Shifting ,
Civil Monetary Penalty ,
Damages ,
Erie Doctrine ,
FTC v Actavis ,
Generic Drugs ,
Hatch-Waxman ,
Judicial Review ,
Patent Litigation ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Rebuttable Presumptions ,
Retroactive Application ,
Reverse Payment Settlement Agreements ,
Rule-of-Reason Analysis ,
State Legislatures